


VCE-004.8

Cat. No.:	HY-128872
CAS No.:	1818428-24-8
Molecular Formula:	C ₂₈ H ₃₅ NO ₃
Molecular Weight:	433.58
Target:	PPAR; Cannabinoid Receptor; HIF/HIF Prolyl-Hydroxylase
Pathway:	Cell Cycle/DNA Damage; GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the COA.



BIOLOGICAL ACTIVITY

Description	VCE-004.8, a semi-synthetic multitarget cannabinoquinoid, is a specific PPARγ and CB₂ receptor dual agonist with potent anti-inflammatory activity ^[1] . VCE-004.8 inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity ^[2] .	
IC ₅₀ & Target	PPAR γ	CB ₂
In Vivo	VCE-004.8 (injection; 20 mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. VCE-004.8 can also significantly ameliorate glucose tolerance, reduce leptin levels (a marker of adiposity) and increase adiponectin and incretins (GLP-1 and GIP) levels ^[1] .	

REFERENCES

[1]. Navarrete C, et al. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. *J Neuroinflammation*. 2018 Mar 1;15(1):64.

[2]. Palomares B, et al. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. *Sci Rep*. 2018 Oct 31;8(1):16092.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA